Plain-English translation of NCT06223048 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new injectable medication called that acts as a tracer dye to help doctors see the retina more clearly during eye imaging. Researchers want to understand how safe this medication is and whether it can improve how glaucoma is diagnosed in people who already have the condition in both eyes.
Current methods of diagnosing and monitoring glaucoma have limitations, and this medication could potentially help doctors detect the disease earlier or track its progression more accurately. By testing this new approach, researchers hope to find better tools for protecting people's vision.
You likely qualify if…
You likely don't qualify if…
You will visit the study site for one appointment where doctors will examine your eyes and take retinal images before and after you receive the medication. You'll receive a single injection of the medication through an IV (intravenous line), followed by more eye imaging, safety checks, and blood tests to measure how your body processes the medication.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Amydis Inc.
Enrollment target
~50 participants
Started
December 2023
Primary completion
November 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
22 Years and older
Last updated on clinicaltrials.gov in July 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Joyce Simpauco
Amydis Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.